Only nine of them (GSTP1, APC, RASSF1, NDRG4, BMP3, two SEPT9 biomarkers, SHOX2 and MGMT) have been included in the clinical guideline application.826 In addition, only two tests have been approved by the FDA: Cologuard (NDRG4 and BMP3), which analyzes stool DNA samples collected as part of a CRC screening protocol, and Epi proColon (SEPT9), which analyzes blood samples collected for the same purpose.826. The gene discussed is BMP3; the disease is colorectal carcinoma.